Replimune Group (NASDAQ:REPL) Given New $21.00 Price Target at HC Wainwright

Replimune Group (NASDAQ:REPL) had its price objective lifted by research analysts at HC Wainwright from $17.00 to $21.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 77.22% from the stock’s current price.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets upped their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.86.

Replimune Group Stock Up 16.9 %

Shares of NASDAQ:REPL opened at $11.85 on Wednesday. The company has a 50 day moving average price of $12.16 and a two-hundred day moving average price of $11.24. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company has a market capitalization of $810.78 million, a PE ratio of -3.89 and a beta of 1.28. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Analysts forecast that Replimune Group will post -2.91 earnings per share for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its holdings in shares of Replimune Group by 14.7% in the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after purchasing an additional 3,374 shares during the period. Algert Global LLC raised its stake in Replimune Group by 5.4% in the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after buying an additional 4,340 shares during the period. Creative Planning raised its stake in Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after buying an additional 4,699 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in shares of Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock worth $385,000 after acquiring an additional 6,216 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.